NKGen Biotech, Inc.’s Post

NKGen CEO, Dr. Paul Y. Song MD, will be presenting at the Allogeneic Cell Therapies Summit on July 12, 2024, at 12:00 pm ET in Boston, MA. Dr. Song will be discussing NKGen’s novel SNK02 allogeneic blood-derived NK cell therapy commercial manufacturing and cryopreservation process along with an update on the SNK02 Phase 1 clinical trial results in refractory solid tumors. See press release at link below for more information. #nkgenbiotech #nkcelltherapy #celltherapy #allogeneic #immunooncology #immunotherapy #oncology

Tumor-infiltrating lymphocytes (TILs).... new to me so I thought I'd share with ya'll what I learned! - TILs are a form of cellular therapy. - A group of TILs taken from a patient’s tumor, so, they may recognize many unique targets. Different from CAR-Ts which target one or two targets. - Used in solid tumors. - No major AEs from TILs. Most AEs come from the chemotherapy regimen or IL-2. https://lnkd.in/gYGPewdM #passionforpatients #oncology

Really amazing to see ! Amtagvi is the first FDA-approved tumor derived T cell immunotherapy. Amtagvi is composed of the patients own T cells. Tumor tissue is removed from the patient during a surgical procedure prior to treatment. The patients’ T cells are separated from the tumor tissue, further manufactured, and then returned to the same patient. Amtagvi is indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.  It will be interesting to see how the TIL culture production will be reduced to less than three weeks without impacting the quality of TIL.

Congratulations Adaptimmune for being the first approved engineering cell therapy for SOLID TUMOUR! Tecelra (an autologous TCR T cell therapy) is also the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. The therapy showed 43% overall response rate in the SPEARHEAD-1 trial, which is a remarkable improvement upon the standard of care. 🔎 Why is this significant for cell therapies? Cell therapies have historically demonstrated suboptimal outcomes for solid tumours because of physical barriers (e.g. vasculature that hinder cell infiltration and migration within solid tumours) and the suppressive immune cells within the tumour microenvironment which promote the production of immune-suppressive-related cytokines, which accelerate the exhaustion of T cells and CAR-T cells (i.e. make the cells lose their ability to kill the cancer cells). Adaptimmune's Tecelra overcoming these hurdles and getting across the approval line is an important milestone for CGT and patients - potentially leading the way for much greater impact for these therapies in oncology. Massive congratulations to the team at Adaptimmune and amazing news for the patients who finally have another treatment option! 🎊 #celltherapy #genetherapy #cellandgenetherapy #celebrate #solidtumour #approval #oncology #patientimpact

🚀 Exciting news in oncology! Adaptimmune is poised for a potentially transformative moment with the upcoming FDA approval of their first-in-class T cell receptor therapy, afami-cel, for synovial sarcoma. This groundbreaking therapy offers hope after a decade without new treatments for this aggressive cancer, primarily affecting younger individuals. At Lampgen Clinical Research, we are proud to support companies like Adaptimmune by providing expert oncology CRAs who ensure clinical trials meet the highest standards of ICH/GCP. Our commitment is to help bring innovative treatments like afami-cel to patients faster and with the assurance of top-tier monitoring. Stay tuned as we continue to support the forefront of cancer therapy advancements! #OncologyResearch #ClinicalTrials #CancerCare #SynovialSarcoma #Adaptimmune #FDAApproval #TCellTherapy #MedicalInnovation #LampgenClinicalResearch #CancerTreatment #HealthcareInnovation #Biotechnology #OncologyCRA ⛓️💥 https://lnkd.in/e2X8WESb

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Adaptimmune gets FDA accelerated approval for T cell receptor cell therapy in rare soft tissue cancer: The FDA granted accelerated approval to a cell therapy for synovial sarcoma, a rare type of cancer typically found in the tissue of the arms and legs. Developed by Adaptimmune Therapeutics, it’s the first cell therapy based on T cell receptors and the second cell therapy for a solid tumor cancer to win approval in the US. The therapy, known as afami-cel, is meant for a subgroup of synovial sarcoma patients whose cancer has spread through their body or can’t be removed via surgery, and who have already received chemotherapy. Adaptimmune plans to market afami-cel as Tecelra. Adaptimmune did not immediately disclose the list price for Tecelra, but CEO Adrian Rawcliffe told Endpoints News ahead of Thursday’s approval that the company plans to price the therapy in the “rare oncology, CAR-T range.” CAR-T therapies can carry a list price of around $500,000 per patient on the high end. To receive the personalized therapy, patients must be tested for certain tumor and cell markers. The company expects that roughly 400 patients per year will be eligible for the treatment. Brian Van Tine “It’s this revolutionary solid tumor therapy,” said Washington University in St. Louis sarcoma specialist Brian Van Tine. “You’re not constantly giving patients therapy to maintain them when they have metastatic disease.” “You can buy just a year or two, or sometimes more time, with doing nothing, and they treat themselves,” said Van Tine, who was an investigator on the clinical trial. Adaptimmune expects to start with just a handful of centers in the US that can administer Tecelra, but hopes to eventually expand to 30 centers across the country, Rawcliffe said. In the Phase 2 clinical trial that helped Tecelra win accelerated approval, 39% of patients with synovial sarcoma saw their tumors shrink at least 30% after receiving the therapy. Adaptimmune needs additional results from a confirmatory study to convert the accelerated approval into a full one. The cell therapy comes with a boxed warning for cytokine release syndrome, a serious immune system overreaction that results from treatment with immunotherapies. In the clinical trial, 71% of patients experienced cytokine release syndrome. Testing for eligibility The therapy is engineered from a patient’s own cells to express T cell receptors against a fragment of a protein called MAGE-A4, which is found in a range of tumors. According to Adaptimmune, about 80% of synovial sarcomas express MAGE-A4. The therapy also requires patients to have a specific cell marker called HLA-A*02 as well. As a result, patients have to be tested for both MAGE-A4 and their HLA type to be eligible for Tecelra. HLA testing is commonly… #lucidquest #genetherapy #celltherapy

Thrilled to share our latest review paper on CAR-T cell therapy in cancer treatment! This breakthrough approach is transforming the landscape of oncology, offering new hope for patients. Dive into our comprehensive analysis to explore the science, advancements, and future directions of CAR-T cell therapy. #CancerResearch #CAR_Therapy #Oncology #MedicalInnovation Click on this link to read this paper - https://lnkd.in/gQDK5uNm

Iovance Biotherapeutics, Inc. has achieved a monumental milestone with the FDA approval of Amtagvi, a novel cell therapy for advanced melanoma. This marks the first approval of a therapy based on tumor-infiltrating lymphocytes (TILs), offering new hope for patients with solid tumors. Key Highlights - 🔷 Amtagvi represents a significant advancement in harnessing the body's immune system to fight cancer. 🔷 It's designed for patients with melanoma that's either inoperable or metastatic, previously treated with other drugs. 🔷 Priced at $515,000, this therapy could lead the way for more innovative treatments in the realm of solid tumors. What's Next? - The approval of Amtagvi could ignite further investment and research into TIL therapies, potentially transforming the landscape of cancer treatment. It's a beacon of hope for many facing this devastating disease. #CancerTreatment #Innovation #Healthcare #TILTherapy #Amtagvi #FDAApproval

How can targeting HER2 transform the treatment of gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC)? HER2 overexpression plays a critical role in driving aggressive tumor growth in both GEA and BTC. By targeting the HER2 pathway, we can interrupt the signaling that fuels cancer progression, leading to improved outcomes for patients. From monoclonal antibodies to cutting-edge therapies in clinical trials, there is a range of strategies available that show significant promise in managing HER2-positive cancers. Empower your oncology practice by exploring the latest strategies: https://ow.ly/J0Aw50TXmzt #Oncology #MedicalEducation #GastricCancers

Gene&Cell Therapy >> Adaptimmune gets FDA accelerated approval for T cell receptor cell therapy in rare soft tissue cancer: The FDA granted accelerated approval to a cell therapy for synovial sarcoma, a rare type of cancer typically found in the tissue of the arms and legs. Developed by Adaptimmune Therapeutics, it’s the first cell therapy based on T cell receptors and the second cell therapy for a solid tumor cancer to win approval in the US. The therapy, known as afami-cel, is meant for a subgroup of synovial sarcoma patients whose cancer has spread through their body or can’t be removed via surgery, and who have already received chemotherapy. Adaptimmune plans to market afami-cel as Tecelra. Adaptimmune did not immediately disclose the list price for Tecelra, but CEO Adrian Rawcliffe told Endpoints News ahead of Thursday’s approval that the company plans to price the therapy in the “rare oncology, CAR-T range.” CAR-T therapies can carry a list price of around $500,000 per patient on the high end. To receive the personalized therapy, patients must be tested for certain tumor and cell markers. The company expects that roughly 400 patients per year will be eligible for the treatment. Brian Van Tine “It’s this revolutionary solid tumor therapy,” said Washington University in St. Louis sarcoma specialist Brian Van Tine. “You’re not constantly giving patients therapy to maintain them when they have metastatic disease.” “You can buy just a year or two, or sometimes more time, with doing nothing, and they treat themselves,” said Van Tine, who was an investigator on the clinical trial. Adaptimmune expects to start with just a handful of centers in the US that can administer Tecelra, but hopes to eventually expand to 30 centers across the country, Rawcliffe said. In the Phase 2 clinical trial that helped Tecelra win accelerated approval, 39% of patients with synovial sarcoma saw their tumors shrink at least 30% after receiving the therapy. Adaptimmune needs additional results from a confirmatory study to convert the accelerated approval into a full one. The cell therapy comes with a boxed warning for cytokine release syndrome, a serious immune system overreaction that results from treatment with immunotherapies. In the clinical trial, 71% of patients experienced cytokine release syndrome. Testing for eligibility The therapy is engineered from a patient’s own cells to express T cell receptors against a fragment of a protein called MAGE-A4, which is found in a range of tumors. According to Adaptimmune, about 80% of synovial sarcomas express MAGE-A4. The therapy also requires patients to have a specific cell marker called HLA-A*02 as well. As a result, patients have to be tested for both MAGE-A4 and their HLA type to be eligible for Tecelra. HLA testing is commonly used for transplants to ensure key proteins that… #lucidquest #genetherapy #celltherapy